TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00224848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palm-Pilot Intervention
Description: Both groups received guideline dissemination, patient activation materials, continuing education (CE) and feedback based on baseline chart audit. The intervention included academic detailing (AD) and a hand-held computerized decision support tool that provided patient-specific, ATPIII-based risk stratification and treatment recommendations. CE sessions offered information relevant to ATPIII and JNC7 and focused on the evidence base. AD offerings focused on strategies to apply concepts to practice and were specific to the randomized arm. Investigators visited each practice at baseline to educate physicians about the guideline and evidence supporting prevention of CVD, and to provide training on use of the Palm tool. Visits were conducted as lunch and learn sessions. The tool was a modified version of NHLBI's PDA decision support program and indicates specific drug therapies and dosages needed to achieve cholesterol reduction and prints documentation. A user's manual was developed.
Study: NCT01864642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative treatment (OMT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative treatment (OMT)
Description: OMT is a form of manual medicine performed by osteopathic physicians
Study: NCT00224848

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Palm-Pilot Intervention
Description: Both groups received guideline dissemination, patient activation materials, continuing education (CE) and feedback based on baseline chart audit. The intervention included academic detailing (AD) and a hand-held computerized decision support tool that provided patient-specific, ATPIII-based risk stratification and treatment recommendations. CE sessions offered information relevant to ATPIII and JNC7 and focused on the evidence base. AD offerings focused on strategies to apply concepts to practice and were specific to the randomized arm. Investigators visited each practice at baseline to educate physicians about the guideline and evidence supporting prevention of CVD, and to provide training on use of the Palm tool. Visits were conducted as lunch and learn sessions. The tool was a modified version of NHLBI's PDA decision support program and indicates specific drug therapies and dosages needed to achieve cholesterol reduction and prints documentation. A user's manual was developed.
Study: NCT01090284

Intervention type: DEVICE
Intervention: Inguinal hernioplasty
Description: A conventional Prosthetic Inguinal Hernioplasty (Trabucco's Technique) will be performed by using polypropylene mesh.

Intervention type: DEVICE
Intervention: Inguinal hernioplasty
Description: A conventional Prosthetic Inguinal Hernioplasty (Trabucco's Technique) will be performed by using polypropylene mesh.
Study: NCT02004600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Description: 1 session of Photodynamic therapy (PDT) on epidermis dysplasia
Study: NCT02155881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Description: Ciclesonide nasal spray 50 mcg/actuation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciclesonide Placebo
Description: Ciclesonide placebo-matching nasal spray
Study: NCT00715455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REG1
Description: ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at approximately 10% the total reversal dose followed by the remaining dose several hours later to counteract RB006 induced anticoagulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REG1
Description: ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at 100% of the total reversal dose to counteract RB006 induced anticoagulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated Heparin
Description: Heparin will be administered per standard of care at sites
Study: NCT04357782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-ascorbic acid
Description: 50 mg/kg L-ascorbic acid infusion given every 6 hours for 4 days (16 total doses)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-ascorbic acid
Description: 50 mg/kg L-ascorbic acid infusion given every 6 hours for 4 days (16 total doses)
Study: NCT04143893

Intervention type: DEVICE
Intervention: Mechanical circulatory support
Description: Patients with cardiogenic shock who underwent MCS
Study: NCT03949049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Citacoline as neuroprotector

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo group
Study: NCT03704597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: Cooling of oral mucosa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: Cooling of oral mucosa
Study: NCT03764215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib 150 MG
Description: 10 participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If this dose is tolerated another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.
Study: NCT02531373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 Medium Dose
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 Medium Dose
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 High Dose
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 High Dose
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 Medium Dose with Alternative Carrier Protein
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg), and Merck Aluminum Phosphate Adjuvant (125 mcg) with alternative carrier protein in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 Medium Dose with Alternative Carrier Protein
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg), and Merck Aluminum Phosphate Adjuvant (125 mcg) with alternative carrier protein in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 High Dose with Alternative Carrier Protein
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) with alternative carrier protein in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 High Dose with Alternative Carrier Protein
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) with alternative carrier protein in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
Study: NCT01031758

Intervention type: OTHER
Group type: OTHER
Intervention: 3H-Cholesterol
Description: A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: 3H-Cholesterol
Description: A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: 3H-Cholesterol
Description: A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
Study: NCT01563562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl
Description: Oral, Single dose
Study: NCT04099056

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurostimulation
Description: Participants will be seated comfortably in a chair and asked to complete simple computer tasks. Participants will receive neurostimulation in the form of Transcranial Magnetic Stimulation (TMS) or Temporal Interference (TI).~TMS: Either during, or just before any of the tasks, participants will receive either repetitive transcranial magnetic stimulation (rTMS) or single pulse TMS. During this, the researchers place a small plastic coil next to the participant's head. The coil will then generate a magnetic pulse, and stimulation will occur during presentation of the visual stimuli on which subjects will conduct behavioral or cognitive tasks.~TI: Either during, or just before, any of the above tasks, participants will receive stimulation with TI. To do so, commercially available gel-based electrodes will be placed on the scalp to target the relevant brain region. The position targeted by the electrodes will be guided by previously defined coordinates.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurostimulation
Description: Participants will be seated comfortably in a chair and asked to complete simple computer tasks. Participants will receive neurostimulation in the form of Transcranial Magnetic Stimulation (TMS) or Temporal Interference (TI).~TMS: Either during, or just before any of the tasks, participants will receive either repetitive transcranial magnetic stimulation (rTMS) or single pulse TMS. During this, the researchers place a small plastic coil next to the participant's head. The coil will then generate a magnetic pulse, and stimulation will occur during presentation of the visual stimuli on which subjects will conduct behavioral or cognitive tasks.~TI: Either during, or just before, any of the above tasks, participants will receive stimulation with TI. To do so, commercially available gel-based electrodes will be placed on the scalp to target the relevant brain region. The position targeted by the electrodes will be guided by previously defined coordinates.
Study: NCT04143893

Intervention type: DRUG
Intervention: Optimal medical treatment
Description: Patients with cardiogenic shock who received optimal medical treatment including vasopressor

Intervention type: DRUG
Intervention: Optimal medical treatment
Description: Patients with cardiogenic shock who received optimal medical treatment including vasopressor
Study: NCT02188771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-articular administration of RegenoGel-SP or hyaluronic acid (HA)
Description: Intra-articular Injection: single injection of RegenoGel SP or 3 injections of HA
Study: NCT02808793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Study: NCT05303077

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutribén Innova® 1
Description: Infants are fed solely with infant formula supplemented with an inactive probiotic and omega 3 fatty acids over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutribén®
Description: Infants are fed solely with infant formula over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's age.
Study: NCT01747577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT05303077

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeed
Description: Infants are breastfeeding solely over the first 6 months of their life, from then on the infants are fed as recommended by their caregiver, as if they are not participating in a research study.
Study: NCT06713629

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiac surgery via median sternotomy
Description: For both groups, the same median sternotomy cardiac surgery procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac surgery via median sternotomy
Description: For both groups, the same median sternotomy cardiac surgery procedure
Study: NCT02083614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: to clamp or release the catheter for 2 days before removal
Study: NCT06713876

Intervention type: DEVICE
Intervention: VA-ECMO-assisted PCI
Description: A total of 220 consecutive patients with VA-ECMO-assisted PCI will be enrolled. Data related to medical history, procedural characteristics, and outcomes were collected. Clinical follow-up will be conducted in the periprocedural and postoperative at 1 month, 1 year, 2 years, 3 years, 4 years, and 5 years.
Study: NCT01122433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation using the C-MAC video laryngoscope
Description: Using the C-MAC video laryngoscope for endotracheal intubation after failed direct laryngoscopy
Study: NCT00338104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Insulin glargine given at 40% of prior stable drip rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Insulin glargine given at 60% of prior stable drip rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Insulin glargine given at 80% of prior stable drip rate.
Study: NCT04017000

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Shape Test
Description: Capturing images of bladder under natural filling conditions images are analysed at a later date for shape change.

Intervention type: OTHER
Group type: OTHER
Intervention: Calibration images
Description: Capturing images of bladder under artificial filling conditions during Urodynamic assessment images are analysed at a later date to inform shape change technology.
Study: NCT03685695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Wear Fitbit Charge 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Complete aimed walking steps

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01303783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (Atacand), 4 mg
Description: 4 mg of candesartan as capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (Atacand), 4 mg
Description: 4 mg of candesartan as capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (Atacand), 8 mg
Description: 8 mg candesartan as capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (Atacand), 8 mg
Description: 8 mg candesartan as capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (Atacand), 8 mg
Description: 8 mg candesartan as capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (Adalat, BAYA1040), 20 mg
Description: 20 mg nifedipine as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (Adalat, BAYA1040), 20 mg
Description: 20 mg nifedipine as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (Adalat, BAYA1040), 20 mg
Description: 20 mg nifedipine as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (Adalat, BAYA1040), 20 mg
Description: 20 mg nifedipine as tablet
Study: NCT01772251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi Icp
Study: NCT01045733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof IQ Toric IOL
Description: AcrySof IQ Toric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AcrySof IQ Aspheric IOL
Description: AcrySof IQ aspheric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
Study: NCT03649945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2，3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2，3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
Study: NCT01045733

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limbal Relaxing Incision (LRI)
Description: An incision was made at the corneal-limbal junction during cataract surgery for the purpose of relaxing corneal curvature, ie., correcting astigmatism.
Study: NCT03649945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nedaplatin
Description: 80 mg/m2,3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nedaplatin
Description: 80 mg/m2,3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endostar
Description: 7.5mg/m2，once a day, continuously dosed for 14 days, then stop for 7 days,3 weeks for one cycle, totally 6 cycles
Study: NCT03425643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline by IV infusion Q3W, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 by IV infusion Q3W, given on cycle days 1 and 8. Given only to participants with squamous NSCLC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m\^2 by IV infusion Q3W, given on cycle days 1 and 8. Given only to participants with squamous NSCLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.
Study: NCT03354390

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell infusion
Description: This is a phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A\*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a dose limiting toxicity (DLT). Patients with evaluable advanced/metastatic ccRCC will be recruited in up to 4 dose levels.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell infusion
Description: This is a phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A\*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a dose limiting toxicity (DLT). Patients with evaluable advanced/metastatic ccRCC will be recruited in up to 4 dose levels.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell infusion
Description: This is a phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A\*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a dose limiting toxicity (DLT). Patients with evaluable advanced/metastatic ccRCC will be recruited in up to 4 dose levels.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell infusion
Description: This is a phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A\*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a dose limiting toxicity (DLT). Patients with evaluable advanced/metastatic ccRCC will be recruited in up to 4 dose levels.
Study: NCT04377633

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Oral handover
Description: Anesthesia handover during surgery will be performed as usual, i.e., oral exchange of pertinent clinical information.
Study: NCT01848717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINTLIFT®
Study: NCT04377633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Checklist handover
Description: Anesthesia handover during surgery will be performed according to a structured handover checklist.